---
title: "Jenscare Scientific Receives FDA Approval for Pivotal Trial of LuX-Valve Plus"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275135581.md"
datetime: "2026-02-06T13:55:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275135581.md)
  - [en](https://longbridge.com/en/news/275135581.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275135581.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275135581.md) | [繁體中文](https://longbridge.com/zh-HK/news/275135581.md)


# Jenscare Scientific Receives FDA Approval for Pivotal Trial of LuX-Valve Plus

Jenscare Scientific Co., Ltd. announced that its independently developed LuX-Valve Plus, a transcatheter tricuspid valve replacement system, has received unconditional Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) for its pivotal clinical trial. This approval allows the company to proceed with the pivotal clinical trial of LuX-Valve Plus in the United States. The device has previously demonstrated positive performance in clinical trials conducted in China, Europe, and other regions. The company intends to advance patient enrollment for the pivotal trial and pursue future commercialization of the product in the U.S. and other global markets. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jenscare Scientific Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260206-12018496), on February 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [iShares US Medical Devices ETF (IHI.US)](https://longbridge.com/en/quote/IHI.US.md)
- [Direxion Daily S&P Biotech Bull 3X ETF (LABU.US)](https://longbridge.com/en/quote/LABU.US.md)
- [ProShares UltraShort Nasdaq Biotech (BIS.US)](https://longbridge.com/en/quote/BIS.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [SPDR® S&P Health Care Equipment ETF (XHE.US)](https://longbridge.com/en/quote/XHE.US.md)
- [Direxion Daily S&P Biotech Bear 3X ETF (LABD.US)](https://longbridge.com/en/quote/LABD.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)

## Related News & Research

- [Stocks in Play: Ventripoint Diagnostics Ltd](https://longbridge.com/en/news/281544776.md)
- [Zevenbergen Capital Investments LLC Invests $32.14 Million in Insulet Corporation $PODD](https://longbridge.com/en/news/281179756.md)
- [Thermo Fisher Scientific Introduces Gibco Cts Compleo Fill and Finish System](https://longbridge.com/en/news/281553253.md)
- [Precigen Details Papzimeos Commercial Launch, Hub Growth and J-Code Catalyst at H.C. Wainwright Chat](https://longbridge.com/en/news/281233412.md)
- [MediBeacon® Transdermal GFR Monitor and Reusable Sensor Receive CE Mark Under European Medical Device Regulation  | VATE Stock News](https://longbridge.com/en/news/281183004.md)